Cost-effectiveness of screening for genital Chlamydia trachomatis

References

• Beagly KW Timms P Chlamyclia trachomatisinfection: incidence, health costs and prospects for vaccine development. J. Reprocl. Immunol. 48(1), 47–68 (2000).
   Google Scholar
• Peeling RW, Brunham RC. Chlamydiae as pathogens. New species and issues. Emerg. Inf. Dis. 2(4), 307–319 (1996).
   Google Scholar
• Clinical Effectiveness Group. National guideline for the management of Chlamyclia trachomatis genital tract infection. Sex. Transm. Infect. 75 (Suppl. 1), S4—S8 (1999).
   Google Scholar
• Quinn TC, Gaydos C, Shepard M et a/. Epidemiologic and microbiologic correlates of Chtamyclia trachomatis infection in sexual partnerships. JAIVIA 276,1737–1742 (1996).
   Google Scholar
• •Most recent study investigating the risk of CT transmission in partnerships.
   Google Scholar
• Cates W Jr., Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am. J. Obstet. Gynecol. 164,1771-1781 (1991).
   Google Scholar
• Hillis S, Black C, Newhall J, Walsh C, Groseclose SL. New opportunities for chlamydia prevention; application of science to public health practice. Sex. Tatum. Dis. 22(3), 197–202 (1995).
   Google Scholar
• Schachter J, McCormack WM, Sweet RL, Thompson KM. Control of chlamydia: a role for every clinician who sees sexually active patients. j Gun. Outcomes Management 4, 60–73 (1997).
   Google Scholar
• Stamm WE, Cole B. Asymptomatic Chlamyclia trachomatisurethritis in men. Sex. 7iansm. Dis. 13,163-165 (1986).
   Google Scholar
• Golden MR, Schillinger JA, Markowitz L, St. Louis ME. Duration of untreated infections with Chlamyclia trachomatis. A review of the literature. Sex. Transm. Dis. 27(6), 329–337 (2000).
   Google Scholar
• •Good review on the duration of CT infection.
   Google Scholar
• Teran S, Walsh C, Irwin KL. Chlamyclia trachomatis infection in women: bad news, good news and next steps in prevention. J. Am. Merl. Womens Assoc. 56(3), 100–104 (2001).
   Google Scholar
• Weström L, Joeseof R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. 7iansm. Dis. 19,185-191 (1992).
   Google Scholar
• ••Landmark paper for PID as a risk-factorfor ectopic pregnancy and infertility.
   Google Scholar
• Weström L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrializedcountries. Ainj Obstet. Gynecol. 138,880–891 (1980).
   PubMed Web of Science ®Google Scholar
• •PID as risk-factor for chronic pelvic pain.
   Google Scholar
• Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JA/V/A 255,3374–3377 (1986).
   Google Scholar
• Yang X, Brunham RC. In pursuit of ahuman chlamydial vaccine. CUI7: Opin. Infect. Dis. 12,47-52 (1999).
   Google Scholar
• Cohen CR, Brunham RC. Pathogenesis of chlamydial induced pelvic inflammatorydisease. Sex. Transm. Infect. 75,21–24 (1999).
   PubMed Web of Science ®Google Scholar
• Hillis SD, Owens LM, Marchbanks PA, Amsterdam LE, MacKenzie WR. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am. J. Obstet. Gynecol. 176,103–107 (1997).
   Google Scholar
• Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB. Oral immunization with an anti-idiotype antibody to the exoglycolipid antigen protects against experimental Chlamyclia trachomatis infection. Nature Med. 2(10), 1116–1121 (1996).
   PubMed Web of Science ®Google Scholar
• Hermann B, Egger M. Genital Chlamyclia trachomatis infections in Uppsala County, Sweden, 1985–1993: Declining rates for how much longer? Sex. Transm. Dis. 22(4), 253–260 (1995).
   Google Scholar
• •Epidemiological evidence that screening programs can reduce the rate of CT infection on a population basis.
   Google Scholar
• CDC (Centers for Disease Control and Prevention). Sexually transmitted disease surveillance 1999 supplement. Chlamydia prevalence monitoring project. Department of Health and Human Services. Division of STD Prevention. CDC, Atlanta, USA (2000).
   Google Scholar
• CDC (Centers for Disease Control andPrevention). Program operations. Guidelines for STD prevention. Areas of special emphasis. CDC, Atlanta, USA (2001).
   Google Scholar
• Walsh C, Anderson LA, Irwin K. The silent epidemic of Chlamydia trachomatis the urgent need for detection and treatment in women. j Womens Health Cend. Based Med. 9(4), 339–343 (2000).
   Google Scholar
• Bundesauschuss der Arzte und Krankenkassen. Mutterschaftsrichtlinien. Bundesanzeiger 37 (February 22,1996)
   Google Scholar
• CDC (Centers for Disease Control and Prevention). Chlamydia in the United States. CDC, Atlanta, USA (April 2001).
   Google Scholar
• Egger M, Low N, Smith GD, Lindblom B, Herrman B. Screening for chlamydial infections and the risk of ectopic pregnancy in a county of Sweden: ecological analysis. Br. Med 316,1776–1780 (1998).
   Google Scholar
• Kamwendo F, Forslin F, Bodin L,Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex. Ttansm. Dis. 23(5), 384–391 (1996).
   Google Scholar
• Kamwendo F, Forslin F, Bodin L, Danielsson D. Programmes to reduce pelvic inflammatory disease-the Swedish experience. Lancet 351 (Suppl. III), 25–28 (1998).
   Google Scholar
• Scholes D, Stergachis A, Heidrich et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N. Engl. Med. 334,1362–1366 (1996).
   PubMed Web of Science ®Google Scholar
• ••First randomized clinical trial showingthat CT screening reduces the incidence of HD.
   Google Scholar
• Howell MR, Quinn TC, Brathwaite W Gaydos CA. Screening women for Chlamydia trachomatis in family planning clinics. The cost-effectiveness of DNA amplifications assays. Sex. Ttansm. Dis. 25(2), 108–117 (1998).
   Google Scholar
• Howell MR, Quinn TC, Gaydos CA 1998. Screening for Chlamydia trachomatisin asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann. Intern. Med. 128(4), 277–284 (1998).
   Google Scholar
• Howell MR, Gaydos JC, McKee KT,Quinn TC, Gaydos CA. Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex. lansm. Dis. 26(9), 519–526 (1999).
   Google Scholar
• Howell MR, McKee KT, Gaydos JC, Quinn TC, Gaydos CA. Point-of-entry screening for C. trachomatis in female army recruits. Who derives the cost savings? Am. j Prey Med. 19(3), 160–166 (2000).
   Google Scholar
• Marrazzo JM, Celum CL, Hillis SD, Fine D, Delisle S, Handsfield III I. Performanceand cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in Women. Sex. lansm. Dis. 24(3), 131–141 (1997).
   Google Scholar
• Paavonen J, Puolakkainen M, Paukku M,Sintonen H. Cost-benefit analysis of first-void urine Chlamydia trachomatisscreening program. Obstet. Cynecol. 92(2), 292–298 (1998).
   Google Scholar
• Postma MJ, Welte R, Van den Hoek JAR,Van Doornum GJJ, Coutinho RA, Jager JC. Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women. Ned. 71jdschr. Ceneeskd 143(13), 677–681 (1999).
   Google Scholar
• Postma MJ, Welte R, Van den Hoek JAR,Jager JC,Van Doornum GJJ, Coutinho RA. Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment. Ned. TUdschr Ceneeskd 143(47), 2383–2385 (1999).
   Google Scholar
• Postma MJ, Welte R, van den Hoek AR,Van Doornum GJJ, Dieke Mulder-Folkerts, Coutinho RA, Jager JC. Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis The importance of re-infection and partner referral. HEPAC 1(2), 103–110 (2000).
   Google Scholar
• Postma MJ, Bakker A, Welte R et al. Screening for asymptomatic infection with Chlamydia trachomatis in pregnancy; favourable cost-effectiveness if prevalence is 3% or more. Ned. Tfidschr Ceneeskd 144(49), 2350–2354 (2000).
   Google Scholar
• Postma MJ, Welte R, van den Hoek AR,Van Doornum GJJ, Jager JC, Coutinho RA. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis. Value in Health 4(3), 266–275 (2001).
   PubMedGoogle Scholar
• Shafer MAB, Pantel RII, Schachter JH. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Anil. Fed. Adoles. Med. 153(2), 119–125 (1999).
   Google Scholar
• Welte R, Kretzschmar M, Leidl R, van denHoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis. A population-based dynamic approach. Sex. 7iansm. Dis. 27(9), 518–529 (2000).
   Google Scholar
• •First scientifically published cost-effectiveness analysis that used a dynamic approach.
   Google Scholar
• CMOs expert advisory group on Chlamydia trachomatis. Department of Health, London, UK (1998).
   Google Scholar
• Genc M, Mar' dh PA. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann. Intern. Med. 124(1), 1–7 (1996).
   Google Scholar
• Genc M, Mar' dh PA. Cost-effective treatment of uncomplicated gonorrhea including co-infection with Chlamydia trachomatis. PharmacoEconomics 12,374–383 (1997).
   Google Scholar
• Gift TL, Pate MS, Hook EW, Kassler W The rapid test paradox: when fewer cases detected lead to more cases treated. A decision analysis of tests for Chlamydia trachomatis. Sex. Tatum. Dis. 26(4), 232–240 (1999).
   Google Scholar
• Haddix AC, Hillis SD, Kassler WJ. The cost-effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex. Transm. Dis. 22,274–280 (1995)
   Google Scholar
• Howell MR, Kassler WJ, Haddix A. Partner notification to prevent pelvic inflammatory disease in women: cost-effectiveness of two strategies. Sex. Tmncm.Dis. 24(5), 287–292 (1997).
   Google Scholar
• •First economic evaluation that included the risk of reinfection due to failed partner referral.
   Google Scholar
• Magid D, Douglas J, Schwartz S. Doxycyline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann. Intern. Med. 124(4), 389–399 (1996).
   Google Scholar
• Marra F, Marra CA, Pattrick D. Cost- effectiveness analysis of azithromycin and doxycyline for Chlamydia trachomatis infections in women. A Canadian perspective. Can. J. Infect. Dis. 8(4), 202–208 (1997).
   Google Scholar
• Nuovo J, Melnikow J, Paliescheskey M, King J, Mowers R. Cost-effectiveness of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. jAm. Boar Fam. Pract. 8(1), 7–16 (1995).
   Google Scholar
• Nyari T, Nyari C, Woodward M, Meszaros G, Deak J, Nagy E, Kovacs L. Screening for Chlamydia trachomatis in asymptomatic women in Hungary. An epidemiological and cost-effectiveness analysis. Acta Obstet. Cynecol Scand. 80(4), 300–306 (2001).
   Google Scholar
• Washington AE, Katz P. Cost and payment source for pelvic inflammatory disease. JA/V/A 266,2565–2569 (1991).
   Google Scholar
• •The presented costs for P11) and its sequelae were frequently used in US cost-effectiveness analyses.
   Google Scholar
• Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing but still substantial. Obstet. Cynecol 95(3), 397–402 (2000).
   Google Scholar
• •Most recent estimate of the direct costs for PID and its sequelae in the USA. These costs are significantly lower than previously reported ones.
   Google Scholar
• Van de Laar MJW, Temorshuiyen F, van den Hoek A. Partner referral by patients with gonorrhea and chlamydial infection. Case-finding observations. Sex. Transm. Dis. 24(6), 334–342 (1997).
   Google Scholar
• Kretzschmar M, van Duynhoven YTHP, Severijnen AJ. Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. Am. J. Epidemic" 144,306–317 (1996).
   Google Scholar
• ••Dynamic model for the simulation of thespread of CT.
   Google Scholar
• Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamyclia trachomatisinfections. Am J. Epidemic" 153(1), 90–101 (2001).
   Google Scholar
• Duncan B, Hart G, Scoular A, Bigrigg A. Qualitative analysis of psychological impact of diagnosis of Chlamyclia trachomatis implications for screening. BE Med. J. 322, 195–199 (2001).
   PubMed Web of Science ®Google Scholar
• ••Psychological problems associated with positive CT test results are presented.
   Google Scholar
• Gencay M, Koskiniemi M, Sakku P et al. Chlamyclia trachomatisseropositivity is associated with perinatal complications. Clin. Infect. Dis. 21,424–426 (1995).
   PubMedGoogle Scholar
• Gencay M, Koskiniemi M, Arnmaia P et al Chlamyclia trachomatisseropositivity is associated both with stillbirth and preterm delivery. APMIS108,584–588 (2000).
   PubMed Web of Science ®Google Scholar
• Andrews WW, Goldenberg RL, Mercer B et al The preterm prediction study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am. J. Obstet. Cynecol 183,662–668 (2000).
   PubMed Web of Science ®Google Scholar
• Rastogi S, Kapur S, Salhan S, Mittal A. Chlamyclia trachomatisinfection in pregnancy: risk factor for an adverse outcome. Br. Domed. Sc]. 56(2), 94–98 (1999).
   Google Scholar
• Claman P, Toye B, Peeling RVV, Jessamine P, Belcher J. Serologic evidence of Chlamyclia trachomatis infection and risk of preterm birth. Can. Med Assoc. 153(3), 259–262 (1995).
   Google Scholar
• Cohen I, Veille JC, Calkins BM. Improved pregancy outcome following successful treatment of Chlamydial infection. JAIVIA263(23), 3160–3163 (1990).
   PubMed Web of Science ®Google Scholar
• Koskela P, Antilla T, Bjorge T etal Chlamyclia trachomatisinfection as a risk factor for invasive cervical cancer. Int. J. Cancer85, 35–39 (2000).
   PubMed Web of Science ®Google Scholar
• Antilla T, Saikku P, Koskela P. Serotypes of Chlamyclia trachomatis infection and risk for development of cervical squamous cell carcinoma. JAMA 285(1), 47–51 (2001).
   PubMed Web of Science ®Google Scholar
• Postema EJ, Remeijer L, van der Meijden WI. Epidemiology of genital chlamydial infections in patients with chlamydial conjunctivitis; a retrospective study. Cenitourin. Med. 72,203–205 (1996).
   Google Scholar
• Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351 (Suppl. 3), 5–7 (1998)
   Google Scholar
• Flemming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 71(1), 3–17 (1999).
   Google Scholar
• Black CM. Current methods of laboratory diagnosis of Chlamyclia trachomatis infections. Clin. Nlicrobiol. Rev 10, 160–84 (1997).
   PubMed Web of Science ®Google Scholar
• CDC (Centers for Disease Control and Prevention). Screening Optimally for Chlamydia: Resource Allocation, Testing and Evaluation Software - SOCRATES. Department of Health and Human Services. Division of STD Prevention. CDC, Atlanta, USA (1999).
   Google Scholar
• Laboratoy Centre for Disease Control (LCDC) Expert Working Group on Canadian Guidelines for Sexually Transmitted Diseases. Canadian STD guidelines. 1998 edition. Division of STD prevention and control, Bureau of HIV/ Aids, STD and TB, LCDC, Ottawa, Canada (1998).
   Google Scholar
• Schachter J. Which test is best for chlamydia? Curr Opin. Infect. Dis. 12, 41–45 (1999).
   Web of Science ®Google Scholar
• Stary A. Chlamydia screening: which sample for which technique? Cenitourin. Med. 73,99–102 (1997).
   Web of Science ®Google Scholar
• Ostergaard L. Diagnosis of urogential Chlamydia trachomatis infection by use of DNA amplification. APMIS89(107 Suppl.), 5–36 (1999).
   Google Scholar
• Dale AW, Homer PJ, Forster GE, Daniels D, Tomlinson D, Brook MG. Management of Chlamydia trachomatis genital tract infection in Genitourinary Medicine Clinics in the United Kingdom's North Thames Region 1999. Int.j STD AIDS12(3), 204–208 (2001).
   Google Scholar
• Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J. Clin. Nlicrobiol. 36(2), 481–485 (1998).
   Google Scholar
• Kreppel J, Patel J, Sposton A et al. The impact on accuracy and cost of ligase chain reaction testing by pooling urine specimens for the diagnosis of Chlamydia trachomatisinfections. Sex. War= Dis. 26(9), 504–507 (1999).
   PubMed Web of Science ®Google Scholar
• Morré SA, Meijer CJLM, Munk C et al. Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. Gun. Mirrobiol 38(4), 1679–1680 (2000).
   Web of Science ®Google Scholar
• Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Warm?. Infect. 74,66–70 (1998).
   PubMed Web of Science ®Google Scholar
• Pate MS, Dixon PB, Hardy K, Crosby M, Hook DI EW. Evaluation of the Biostar OIA assay with specimen from women attending a sexually transmitted disease clinic. J. Gun. Mirrobiol 36(8), 2183–2186 (1998).
   Google Scholar
• Chernesky M, Jang D, Krepel J, Sellors J, Mahony J. Impact of reference standard sensitivity on accuracy of rapid antigen detection assays and a leukocyte esterase dipstick for diagnosis of Chlamydia trachomatis infection in first-void urine specimens from men. J. Gun. Nlirrobiol 37(9), 2777–2780 (1999).
   Google Scholar
• Butt A, McCartney R, Walker A, Scoular A. Economic advantages of ligase chain reaction for diagnosis of genital Chlamydia trachomatis infection in GUM clinic offenders. Sex. Tiansm Infect. 77(3), 227–228 (2001).
   PubMed Web of Science ®Google Scholar
• Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of chlamydia trachomatis infection. J. Gun. Microbial. 36(1), 94–99 (1998).
   Google Scholar
• CDC (Centers for Disease Control and Prevention). 1998 Guidelines for treatment of sexually transmitted diseases. MMWR Morb. Mortal Wkly Rep. 47(no. RR-1) (1998).
   Google Scholar
• Davies HD, Wang EEL, with the Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Can. Merl Assoc.j 154,1631–1644 (1996).
   Google Scholar
• Lea AP, Lamb HM. Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogential Chlamydia trachomatis infections in women. PharmacoEconomic512(5), 596–611 (1997).
   Google Scholar
• Hillis SD, Coles FB, Litchfield B etal Doxycycline and azithromycine for prevention of chlamydial persistence or recurrence one month after treatment in women. Sex. 7iansm. Dis. 25(1), 5–10 (1998).
   Google Scholar
• Bachmann LH, Stephens J, Richey CM, Hook EW. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex. Transm. Dis. 26, 272–278 (1999).
   PubMed Web of Science ®Google Scholar
• Dicker LW, Mosure DJ, Levine WC.Chlamydia positivity versus prevalence. What's the difference? Sex Transm. Dis.25(5), 251–253 (1998).
   Google Scholar
• CDC (Centers for Disease Control and Prevention). Tracking the hidden epidemics. Trends in STDs in the United States 2000. CDC, Atlanta, USA (2000).
   Google Scholar
• Burstein GR, Gaydos CA, Diener-West M, Howell MR, Zenilman JM, Quinn TC. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAIVIA 12(6), 521–526 (1998).
   Google Scholar
• Hiltunen-Back E, Haikala 0, Kautiainen H, Paavonen J, Reunala T A nationwide sentinel clinic survey of Chlamydia trachomatis infection in Finland. Sex. Tatum. Dir. 28(5), 252–258 (2001).
   Google Scholar
• Van den Hoek JAR, Mulder-Fokkerts DKF, Coutinho RA, Dukers NHTM, Buimer M, Van Doornum GJJ. Opportunistic screening for genital infections with Chlarnydia trachomatisamong the sexually active population of Amsterdam I. Over 90% participation and almost 5% prevalence. Ned. Tfidschr. Ceneeskd. 143(13), 668–671 (1999).
   Google Scholar
• Malkin JE, Prazuck T, Bogard M et al Screening of Chlamydia trachomatis genital infection in a young Parisian population. Sex. Tatum. Infect. 75,188–189 (1999).
   PubMed Web of Science ®Google Scholar
• Vuylsteke B, Vandenbruaene M, Vandenbulcke P, Van Dyck E, Laga M. Chlarnydia trachomatisprevalence and sexual behaviour among female adolescents in Belgium. Sex. 7iansm. Infect. 75,152-155 (1999).
   Google Scholar
• Burstein GR, Zenilman JM, Gaydos CA etal.Predictors of repeat Chiamydia bachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Trarrsm. Infect. 77(1), 26–23 (2001).
   Google Scholar
• Gershman IKA, Barrow JC. A tale of twosexually transmitted diseases. Prevalences and predictors of chlamydia and gonorrhea in women attending Colorado family planning clinics. Sex. 7iansm. Dis. 23(6), 481–488 (1996).
   Google Scholar
• Gunn RA, Hillis SD, Shirey P, Warterman SH, Greenspan JR. Chlamydia trachomatis infection among hispanic women in the California-Mexico Border Area, 1993: establishing screening criteria in a primary care setting. Sex. Transm. Dis. 22(6), 329–334 (1995).
   Google Scholar
• Handsfield HH, Jasman LL, Roberts PL, Hanson VW, Kothenbeutel RL, Stamm WE. Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics. JAMA 255(13), 1730–1734 (1986).
   PubMed Web of Science ®Google Scholar
• Mangione-Smith R, O'Leary J, McGlynn EA. Health and cost-benefits of chlamydia screening in young women. Sex. Transm. Dis. 26(6), 309–316 (1999).
   Google Scholar
• Stergachis A, Scholes D, Heidrich FE, Sherer DM, Holmes KIK, Stamm WE. Selective screening for Chlamydia trachomatis infection in a primary care population of women. Am. J. Epidemiol 138(3), 143–153 (1993).
   Google Scholar
• Van Duynhoven YTHP, van de Laar MJW, Fennema JSA, van Doornum GJJ, van den Hoek JAR. Development and evaluation of screening strategies for Chlamydia trachomatis infection in a STD clinic. Cenitourin. Med. 71,375–381 (1995).
   PubMedGoogle Scholar
• Weinstock HS, Bolan GA, Kohn R, Balladares C, Back A, Oliva G. Chlarnydia trachomatis infection in women: a need for universal screening in high prevalence populations? Am. J. Epidemiol 135(1), 41–47 (1992)
   Web of Science ®Google Scholar
• Ostergaard L. Andersen B, Olesen F, Moller JK. Efficacy of home sampling for screening of Chlamydia trachomatis randomized study. BE Med. J. 317,26–27 (1998)
   Google Scholar
• Ostergaard L. Andersen B, Olesen F, Moller JK. Home sampling versus conventional swab sampling for screening of Chlarnydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin. Infect. Dis 31,951–957 (2000)
   Google Scholar
• ACOG (American College of Obstetricians and Gynecologists), ACOG Committee on Primary Care. Committee Opinion No. 229. ACOG, Washington DC, USA (1999).
   Google Scholar
• USPSTF (US Preventive Services Task Force). Screening for chlamydial infection. Recommendations and rationale. Am. Prey Merl 20(3S), 90–94 (2001).
   Google Scholar
• Tanaka M, Nakayama H, Sagiyama K et al Evaluation of a new amplified enzyme immunoassay (ETA) for the detection of Chlamydia trachomatisin male urine, female endocervical swab and patient obtained vaginal swab specimens.Clin. Path. 53(5), 350–354 (2000).
   Web of Science ®Google Scholar
• Erbelding E, Quinn TC. The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect. Dis. Clin. North Am. 11 (4), 889–903 (1997).
   Google Scholar
• Stevens RS, Kalman S, Lammel C. Genome sequence of an obligate intracelluar pathogen of humans: Chlamydia trachomatis. Science282,754–759 (1998).
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance (NCQA). The Health Plan Employer Data and Information SetIT and www.ncqa.org/Programs/HEDIS/
   Google Scholar